Celularity Inc (CELU)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $20.45M
Last updated: Nov 17, 2026 at 4:15 PM ET
Celularity Inc (CELU) Statistics
Celularity (CELU) has a market cap of $20.45M. It kept -269.61% of revenue as net income over the last 12 months. Revenue fell 63.02% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $20.45M |
|---|---|
| Latest price (Nov 17, 2026) | $0.56 |
Key Dates
| Last Earnings Date | Oct 20, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 63.59% over 52 weeks and trades 50.88% below its 50-day average.
| Beta (1Y) | 1.94 |
|---|---|
| 52-Week Change | -63.59% |
| 1-Month Change | -51.35% |
| 3-Month Change | -27.47% |
| 6-Month Change | -30.00% |
| 5-Year Change | -98.81% |
| Total Return (1Y) | -63.59% |
| Total Return (3Y CAGR) | -35.44% |
| Total Return (5Y CAGR) | -61.82% |
| Max Drawdown (1Y) | -73.13% |
| Max Drawdown (3Y) | -91.89% |
| Sharpe Ratio (1Y) | -0.86 |
| Correlation with SPY (1Y) | 0.20 |
| 50-Day Average | $1.14 |
| 200-Day Average | $1.05 |
| 52-Week Range | $0.56 to $2.55 |
| RSI (14 Days) | 29.8 |
| Average Volume (20 Days) | 187.96K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.11x current liabilities.
| Current Ratio | 0.11x |
|---|---|
| Quick Ratio | 0.10x |
| Interest Coverage | -19.29x |
Returns and Efficiency
| Return on Assets (ROA) | -95.37% |
|---|---|
| Return on Capital Employed (ROCE) | -123.02% |
| ROA (5Y Average) | -57.23% |
| ROIC (5Y Average) | 83.21% |
| Asset Turnover | 0.17x |
| Inventory Turnover | 31.04x |
| Receivables Turnover | 3.70x |
| Cash Conversion Cycle | -280 days |
Scores
CELU has an Altman Z-Score of -16.36, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -16.36 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $17.49M over the last 12 months.
| Revenue | $17.49M |
|---|---|
| Revenue Growth (YoY) | -63.02% |
| Gross Profit | -$1.06M |
| Operating Income | -$58.49M |
| Pretax Income | -$47.14M |
| Net Income | -$47.14M |
| EBITDA | -$38.07M |
| EBIT | -$44.81M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $586.00K |
|---|---|
| Working Capital | -$53.29M |
| Shareholder Equity | -$35.53M |
| Tangible Book Value | -$49.21M |
| Total Assets | $96.17M |
| Total Liabilities | $131.70M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $0 of capital spending, operating cash flow left -$9.87M of free cash flow.
| Operating Cash Flow | -$9.87M |
|---|---|
| Capital Expenditures | $0 |
| Free Cash Flow | -$9.87M |
| FCF Per Share | -$0.30 |
| Depreciation and Amortization | $6.74M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -334.47%.
| Gross Margin | -6.07% |
|---|---|
| Operating Margin | -334.47% |
| Pretax Margin | -269.58% |
| Net Margin | -269.61% |
| EBITDA Margin | -217.73% |
| EBIT Margin | -256.29% |
| FCF Margin | -56.43% |
| Gross Margin (5Y Average) | 34.35% |
Growth
Revenue grew 13.88% a year over 3 years.
| Revenue Growth (3Y CAGR) | +13.88% |
|---|---|
| Revenue Growth (5Y CAGR) | +13.21% |
Dividends and Yields
CELU does not pay a dividend. Its free cash flow yield is -59.59%.
| FCF Yield | -59.59% |
|---|---|
| Shareholder Yield | 0.91% |
Stock Splits
The last split was a 1-for-10 reverse split on Feb 29, 2024.
| Last Split Date | Feb 29, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 3 similar companies, CELU has the lowest P/S.
P/S RatioPeer median 16.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -93.31%
| P/S Ratio | 0.9x vs 16.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -63.02% vs -93.31% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CELU
What is CELU's market cap?
Celularity has a market cap of $20.45M.
How many shares of CELU are outstanding?
Celularity has 29.34M shares outstanding. The count is up 11.37% from a year earlier.
Does CELU pay a dividend?
No. Celularity does not pay a dividend.
CELU pages: Overview, Charting, Earnings, Financials, Statistics, Competitors